Nuclear imaging devices market seen reaching $4.71B by 2030

The nuclear imaging devices and equipment market is projected to grow from $4 billion in 2025 to $4.71 billion by 2030, according to The Business Research Company. Growth is tied to chronic disease demand, hybrid imaging adoption and AI-enabled diagnostics, with Western Europe leading the market in 2025.

Why it matters: - Nuclear imaging is a core diagnostic tool for chronic disease care, including cancer, heart disease and other long-term conditions. - The market outlook signals continued demand for advanced imaging systems that improve early detection, treatment monitoring and workflow efficiency. - The forecast points to growing adoption of hybrid systems and AI tools across hospitals and specialty clinics.

What happened: - The Business Research Company projected the nuclear imaging devices and equipment market will rise from $4 billion in 2025 to $4.13 billion in 2026. - The market is expected to reach $4.71 billion by 2030, implying a 3.3% CAGR through the forecast period. - Western Europe held the largest regional market share in 2025. - North America ranked as the second-largest market in 2025. - The report also covers Asia-Pacific, South East Asia, Eastern Europe, South America, the Middle East and Africa. - A free sample of the report is available. - The full market report is also available.

The details: - Nuclear imaging devices use small amounts of radioactive substances to diagnose medical conditions. - The devices are used in cardiology, obstetrics and gynecology, vascular medicine, urology and other specialties. - The report said growth in the historical period was driven by more chronic disease cases, expansion of nuclear medicine departments, wider availability of radiotracers, adoption of advanced diagnostic imaging protocols and greater need for early disease detection. - Forecast growth is expected to be supported by higher investment in precision diagnostics, broader use of hybrid imaging technologies, development in nuclear cardiology and oncology imaging, low-dose imaging solutions and AI-driven diagnostic tools. - Key trends include expanding use of PET/CT and SPECT/CT systems, stronger demand for oncology imaging, AI in image reconstruction, growing molecular imaging applications and more emphasis on diagnostic accuracy and workflow efficiency. - The World Health Organization projected in February 2024 that global cancer cases could exceed 35 million by 2050, up 77% from an estimated 20 million in 2022.

Between the lines: - The forecast suggests the market is mature enough to grow steadily, but not fast enough to signal a breakout cycle. - Chronic disease prevalence remains the central demand driver, which makes oncology and cardiology the most commercially important imaging segments. - AI and hybrid imaging are moving from optional upgrades to core product features as providers look for better image quality and faster diagnosis.

What's next: - The market’s next phase will likely center on product upgrades rather than broad geographic expansion. - Vendors will keep pushing hybrid imaging, low-dose systems and AI-enabled reconstruction to win hospital and specialty-care buyers. - The Business Research Company said its 2026 reports include market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel dashboards and trend analysis. - The company also provided contact details for expert inquiries and listed its social media channels, including LinkedIn, Facebook and X.